jjs

"patience is bitter, but its fruit is sweet." hopefully.
photo:"Cloud Gate" (aka "The Bean") ©jjs
🇺🇸🌿

[jjs @twojayess]

@jfberke not a good look. George about to sell......soon?

[jjs @twojayess]

@Shrek_420_ "we like to be first" Boris doesn't seem to be in the pole position.

[jjs @twojayess]

$TCNNF
the hoops @rivers_kim is jumping through per that Claude dude:
What Trulieve just did
They split themselves into two pieces through a deconsolidation transaction, effective June 3,
2026:
TCNNF parent (the remaining Trulieve) — now holds ONLY the medical cannabis business. This
is what the stock represents going forward, on consolidated basis.
Harvest Enterprises, LLC — a new Delaware LLC that now holds the "mixed-use" (adult-use)
cannabis business. Deconsolidated from Trulieve's financials.
The mechanism: Trulieve sold a 10% voting/economic stake in Harvest to Whitley Holding
05192026, LLC for $14.8 million. Trulieve's subsidiary keeps 90% of the economics — but via
Exchangeable Units that are non-voting and non-dividend-receiving, convertible into voting
Class B units only when "NYSE permits the listing of companies that consolidate the financial
statements of companies that cultivate, distribute or possess marijuana for non-medical uses"
(the "Triggering Event"). Translation: when full adult-use rescheduling happens, Trulieve can pull
the adult-use business back. Until then, it's structurally deconsolidated for GAAP and NYSE
listing purposes.
Why this is a BFD
This is the most aggressive structural response to medical-only Schedule III rescheduling by
any major MSO. The reasoning:
NYSE listing standards won't accept companies that consolidate financials with non-medical
(Schedule I) cannabis operations. Curaleaf and Verano's reverse-split path solves the share
price listing threshold but doesn't solve the consolidated financials problem. Trulieve's
structure solves the financials problem. They're presenting a medical-only Trulieve to the NYSE
— which, given Trulieve's 69.7% Florida medical concentration per ATB, is the cleanest "pure-
play medical cannabis" investment case in the sector.
What the pro forma financials show:
Revenue drops from $1.18B (2025) to $903.6M (medical only)
$688.6M one-time loss on deconsolidation (non-cash, GAAP-driven)
$696.4M of uncertain tax position liabilities drops to $538.3M — meaningful 280E balance
sheet cleanup
$188.5M equity-method investment in Harvest now sits on the balance sheet
$14.8M cash received from Whitley
The Whitley structure
This is the key engineering. Whitley Holdings 05192026, LLC (note the date in the name — May
19, 2026 — entity formed specifically for this) is at 308 East Park Avenue, Tallahassee —
Trulieve's hometown. Frank Whitley and Rudy Rowe got 2 of 3 Harvest board seats; Kim Rivers
got the Trulieve-side seat. Trulieve's board representative is explicitly barred from voting on
annual business plans, executive officer decisions, and compensation matters while
Exchangeable Units remain outstanding.
This means the deconsolidation has real corporate-governance substance. It's not a paper-
only carve-out. The Whitley group genuinely controls Harvest's operations. That substance is
what makes the GAAP deconsolidation defensible and what NYSE will need to accept.
The dividend structure to Whitley tells you something about the deal economics: $270K/month
pre-rescheduling, $1.27M/month for 16 months post-rescheduling, then $370K/month for 104
months. On Whitley's $14.8M investment, that's roughly $59M in dividend stream over ~120
months — plus the eventual put right at FMV. Whitley is being well compensated to be the
structurally trusted independent party.
First-mover implications
Trulieve is now ahead of every other MSO on the path to NYSE listing:
They've solved the listing-standard problem at the financials level, not just share price
Curaleaf and Verano have done reverse splits but neither has deconsolidated
If NYSE accepts this structure, Trulieve gets listed first — and captures institutional flow and
index access before peers
The Kim Rivers political-asset thesis (Wiles connection, executive order influence) just became
operationally instantiated. This is the level of structural creativity that requires confidence the
regulatory path is supportive.
Risks worth flagging
NYSE acceptance is not certain. They've been "in consultation" but this is a novel structure. If
NYSE rejects the deconsolidation as a sham, the entire premise fails.
SEC scrutiny. The deconsolidation has to pass GAAP scrutiny under ASC 810 (consolidation).
The non-voting, non-participating structure of the Exchangeable Units is the mechanism — but
SEC could challenge.
Near-term reported financials look uglier. $688M one-time loss on deconsolidation, revenue
down ~24%, will hit Q2 2026 reported results. Sophisticated investors will see through this;
less-sophisticated initial reactions could pressure the stock.
Adult-use thesis preservation depends on the Triggering Event actually happening. If broader
rescheduling drags or fails, Trulieve's economic interest in Harvest stays trapped in non-voting
form indefinitely.
Bottom line for TCNNF
This is the most aggressive medical-only rescheduling play in the sector and validates the Kim
Rivers / Florida-medical thesis at the corporate-structure level. Trulieve is now positioned to
potentially be the first NYSE-listed MSO, with a clean medical-only investment case for
institutional buyers who otherwise can't touch cannabis. Your tier structure for TCNNF remains
operationally intact (no share-level change), but the upside thesis just got materially sharper if
NYSE accepts the structure.
Watch for: NYSE listing application filing date and any preliminary indication of acceptance.
That's the next milestone

$MSOS

[jjs @twojayess]

on the road to readiness, $CURLF did a reverse, followed by $VRNO; wonder what's $CRLBF plan? @CharlesBachtell

[Chicago Bears @ChicagoBears]

Oh yeah, we're SO back 🙂‍↕️

[jjs @twojayess]

you should be aware that in using Claude for sector research,I have constantly run into the following issues: *Repeated corrections don't fix errors that have been cited; the model produces new versions of the same failure
*Long threads accumulate errors that compound *Confident framing maintained even when underlying data is wrong
*Visual data parsing failed 3 times on a standard brokerage screen I provided directly
*Placed NVDA's earnings print in the future when the current date was previously provided and the print was the prior day
*Missed a public stock split that invalidated equity analysis and persisted into a final deliverable
*Web search returns stale data; presented as live without flagging the limitation

[jjs @twojayess]

@AnthropicAI @DarioAmodei @AmandaAskell @jackclarkSF - you should be aware that in using Claude for sector research,I have constantly run into the following issues:
*Repeated corrections don't fix errors that have been cited; the model produces new versions of the same failure
*Long threads accumulate errors that compound
*Confident framing maintained even when underlying data is wrong
*Visual data parsing failed 3 times on a standard brokerage screen I provided directly
*Placed NVDA's earnings print in the future when the current date was previously provided and the print was the prior day
*Missed a public stock split that invalidated equity analysis and persisted into a final deliverable
*Web search returns stale data; presented as live without flagging the limitation

[jjs @twojayess]

@RoKhanna @RepThomasMassie your good friend is an anti-Semite, Ro.

[jjs @twojayess]

@Insider_Brief @Shrek_420_ yep

[jjs @twojayess]

@joceyreyes209 @DanielTNiles thus, the of sorts. however for those who held onto shares, those MRVL shares....

[jjs @twojayess]

@DanielTNiles @joceyreyes209 rivalry of sorts with Ancor Communications which was bought by QLogic which was in turn was bought by Cavium which was in turn bought by Marvell.

[jjs @twojayess]

@V_arrell @vedadi @MikePal10 but but but he's the "Market Oracle. NO ONE better at it on the planet". 🤦‍♂️

[jjs @twojayess]

@CannaVestments @Bkov9

[jjs @twojayess]

@CannaVestments @jfberke last night Boris seemed pretty pretty confident that the ban will go into effect; wonder if/why Target thinks otherwise.

[jjs @twojayess]

@V_arrell @AlderLaneEggs @BCobblaw

[jjs @twojayess]

@gregrieben the move is because of news

[jjs @twojayess]

@srg444 you want to hazard a guess as to what the "big" thing is?